77 -3 (65) 2024 - Oblokulov A.R., Hodiyeva D.I. - CLINICAL AND LABORATORY CHARACTERIZATION OF SARS-COV-2 INFECTION

CLINICAL AND LABORATORY CHARACTERIZATION OF SARS-COV-2 INFECTION

Oblokulov A.R. Bukhara State Medical Institute named after Abu Ali ibn Sina

Hodiyeva D.I. Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

The significance of D-dimer coagulation (DD), prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and fibrinogen (Fg) and PCT in predicting the severity and prognosis of COVID-19 was studied. Violation of the function of blood coagulation occurred in almost all, more often in severe patients. Indicators of hemostatic homeostasis, such as D-dimer, prothrombin time, fibrinogen and procalcitonin, can be used as predictors of disease severity in patients.

Keywords: COVID-19, prothrombin time, D-dimer, antiphospholipid antibodies, procalcitonin.

First page

411

Last page

419

For citation: Oblokulov A.R., Hodiyeva D.I. - CLINICAL AND LABORATORY CHARACTERIZATION OF SARS-COV-2 INFECTION//New Day in Medicine 3(65)2024 411-419 https://newdayworldmedicine.com/en/article/3758

List of References

  1. World Health Organization. Novel Coronavirus (2019-nCoV) situation reports. https://www.worldometers.info/coronavirus/ Accessed: 28 Sept. 2021.
  2. Oblokulov A.R., Musaeva D.M., Elmuradova A.A. (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). // New Day in Medicine. 2020;2(30/2):110-115.
  3. Bikdeli B, Madhavan MV, Jimenez D et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. // JACC. 2020. doi:10.1016/j.jacc.2020.04.031.
  4. Husenova Z. Z, Oblokulov A. R. (2021). Clinical and epidemiological characteristics of patients with severe form of COVID-19. Central asian journal of medical and natural sciences, 2021; 2(3):282-285. https://doi.org/10.47494/cajmns.v2i3.213.
  5. Cao Y., Liu X., Xiong L. et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS CoV 2: a systematic review and meta analysis. // J. Med. Virol., 2020; doi: 10.1002/jmv.25 822.,
  6. Abdurashid Rahimovich Oblokulov, Zilola Zohirovna Husenova, Maksudjon Muzaffarovich Ergashev. (2021). Procalcitonin as an Indicator of Antibacterial Therapy in Covid-19. Annals of the Romanian Society for Cell Biology, 2021; 25(3):5220–5224.
  7. Iba T., Levy J.H., Levi M. и соавт.: Coagulopathy of coronavirus disease 2019. Crit. Care Med., 2020; doi: 10.1097/CCM.0 000 000 000 004 458.
  8. Niyazov G.E., Oblokulov A.R., Pondina A.I. et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients // New Day in Medicine. 2020;4(32):110-115.
  9. Levi M., Thachil J., Iba T., Levye J.H.: Coagulation abnormalities and thrombosis in patients with COVID 19. Lancet Haematol. 2020; 7:e438–e440.
  10. Wang D, Hu B, Hu C et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020.,
  11. Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. // Lancet. 2020;395:507-513.
  12. Han H, Yang L, Liu R et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. // Clin Chem Lab Med. 2020;58:1116-1120.
  13. Tao J, Song Z, Yang L. et al. Emergency management for preventing and controlling nosocomial infection of 2019 novel coronavirus: implications for the dermatology department. // Br J Dermatol. 2020;182:1477-1478.
  14. Wang L, He WB, Yu XM. et al. Prolonged prothrombin time at admission predicts poor clinical outcome in COVID-19 patients. // World J Clin Cases 2020; 8(19): 4370-4379.
  15. Oblokulov A. R., Niyozov G.E. (2020) Clinical and epidemiological characteristics of patients with COVID-19 // International Journal of Pharmaceutical Research; 2020;12(4):3749-3752.
  16. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. // J Clin Invest. 2020;130(5):2620-9.
  17. Heesom L, Rehnberg L, Nasim-Mohi M, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. // J Glob Antimicrob Resist. 2020;22:782-4.
  18. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. // BMJ. 2020;368:m1091.
  19. Guan, W., Ni, Z., Hu, Y. et al.Clinical characteristics of 2019 novel coronavirus infection in China // N Engl J Med. 2020; 382(18):1708-1720.
  20. Williams EJ et al. (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely withheld in patients admitted to hospital with SARS-CoV-2 infection. medRxiv.

    file

    download